Comparison of gastric and small-bowel transit time between Lubiprostone, and placebo-controlled in healthy volunteers : a double-blind, placebo-controlled study by capsule endoscopy

Comparison of gastric and small-bowel transit time between Lubiprostone, and placebo-controlled in healthy volunteers : a double-blind, placebo-controlled study by capsule endoscopy - Comparison of gastric and small-bowel transit time between Lubiprostone, and placebo-controlled in healthy volunteers : a double-blind, placebo-controlled study by capsule endoscopy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010965

Enrollment

Registered

2013-07-26

Start date

2013-07-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers

Interventions

The group who takes Lubiprostone The group who takes Placebo

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patient who fills everything the following 1) Patient of 20 years or more 2) Patient who gives written informed consent

Exclusion criteria

Exclusion criteria: The patient who collides with either the following assumes that it doesn't put it in to the examination 1) Drug allergy 2) Subjects with malignancy 3)Others

Design outcomes

Primary

Measure	Time frame
gastric and small-bowel transit time	—

Countries

Japan

Contacts

Public ContactMasahiko Inamori

Yokohama City University Graduate School of Medicine Gastroenterology Division

inamorim@med.yokohama-cu.ac.jp045-787-2640

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026